<DOC>
	<DOCNO>NCT01234402</DOCNO>
	<brief_summary>An open-label , multicenter , randomize , Phase 2 trial patient unresectable , locally advanced metastatic breast cancer previously treat anthracycline taxane therapy receive ramucirumab DP IMC-18F1 administer every-21-day cycle ( combination oral capecitabine therapy ; capecitabine administer twice day Days 1-14 cycle ) . Approximately 150 patient randomize 1:1:1 ratio either ramucirumab DP IMC-18F1 combination capecitabine ( Arm A Arm B , respectively ) capecitabine monotherapy ( Arm C ) . Randomization stratify triple-negative receptor status ( estrogen receptor-negative , progesterone receptor-negative , human epidermal growth factor receptor-2 [ HER2/neu ] -negative ) ( yes/no ) receipt prior antiangiogenic therapy . Treatment study medication ( ) continue disease progression , development unacceptable toxicity , noncompliance withdrawal consent patient , investigator decision . Capecitabine dose reduction set significant myelosuppression , hand-and-foot syndrome , diarrhea require .</brief_summary>
	<brief_title>Study IMC-18F1 Ramucirumab DP Combination With Capecitabine Capecitabine Previously Treated Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>The patient histologically cytologically confirm breast cancer time study entry either Stage III disease amenable curative therapy Stage IV disease Has measurable nonmeasurable disease Has Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Has receive prior anthracycline therapy Has receive prior taxane therapy Patients HER2positive disease must progress follow trastuzumab Patients hormone receptorpositive disease must progress follow hormone therapy Has receive ≤ 3 prior chemotherapy regimen set ( regimen define agent [ ] administer 1 cycle ; sequential neoadjuvant/adjuvant treatment consider 1 regimen ) Has complete prior radiotherapy ≥ 4 week prior randomization Has complete prior hormonal therapy ≥ 2 week prior randomization Has AEs resolve Grade ≤ 1 National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE v 4.0 ) clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy Has adequate hematologic , coagulation , hepatic renal function Does : cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis Has urinary protein ≤ 1+ dipstick routine urinalysis ; urine protein ≥ 2+ , 24hour urine collection must demonstrate &lt; 1000 mg protein 24 hour allow participation study Agrees use adequate contraception study period 12 week last dose study medication Has concurrent active malignancy adequately treat nonmelanomatous skin cancer , curatively treated cervical carcinoma situ , noninvasive carcinoma situ neoplasm . A patient previous history malignancy eligible , provide diseasefree interval &gt; 3 year Has know sensitivity capecitabine , component , drug formulate polysorbate 80 Has know sensitivity 5FU Has know dihydropyrimidine dehydrogenase deficiency Has receive prior capecitabine treatment advance breast cancer Has receive investigational therapy within 2 week prior randomization Has receive bevacizumab within 4 week prior randomization Has receive 1 prior antiangiogenic agent breast cancer Has know sensitivity agent similar biologic composition ramucirumab DP IMC18F1 , agent specifically target VEGF Has acute/subacute bowel obstruction history chronic diarrhea require ongoing medical intervention Has history uncontrolled hereditary acquire bleed thrombotic disorder Has experience Grade ≥ 3 bleed event within 3 month prior randomization Is receive prophylactic therapeutic anticoagulation warfarin oral anticoagulant Has uncontrolled intercurrent illness , include , limited uncontrolled hypertension , symptomatic anemia , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , psychiatric illness/social situation , serious uncontrolled medical disorder opinion investigator Has experience arterial thrombotic thromboembolic event , include , limited myocardial infarction , transient ischemic attack , cerebrovascular accident within 6 month prior randomization Has brain metastasis , uncontrolled spinal cord compression , leptomeningeal disease Has ongoing active infection require parenteral antibiotic , antifungal , antiviral therapy Has receive prior allogeneic organ tissue transplantation Has undergone major surgery within 4 week prior randomization , subcutaneous venous access device placement within 7 day prior randomization Has serious nonhealing wound , ulcer , bone fracture within 4 week prior randomization Has know HIV AIDS infection Has elective plan major surgery perform course trial Patient pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>